Skip to main content
Clinical Trials/DRKS00024815
DRKS00024815
Completed
Phase 3

The effects of esketamine and treatment expectation in acute major depressive disorder:A pharmacological fMRI-study - Expect

Phillips Universität Marburg0 sites165 target enrollmentStarted: March 22, 2021Last updated:

Overview

Phase
Phase 3
Status
Completed
Sponsor
Phillips Universität Marburg
Enrollment
165

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomized controlled study
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to 65 Years (—)
Sex
All

Inclusion Criteria

  • 1\. a current depressive episode lasting at least four weeks
  • 2\. an initial score of at least 7 (corresponding to a mild degree of depression) on the Montgomery Åsberg Depression Rating Scale (MADRS)
  • 3\. Negative serum pregnancy test in women of childbearing potential.
  • 4\. Patients with reproductive potential must agree to maintain highly effective methods of contraception by practicing abstinence or by using at least two methods of birth control from the date of consent through the end of the study. If abstinence could not be practiced, a combination of hormonal
  • contraceptive (oral, injectable, or implants) and a barrier method (condom, diaphragm with a vaginal spermicidal agent) has to be used.

Exclusion Criteria

  • 1\. psychotic symptoms (ascertained using SCID\-5 Interview measured by module A\-E)
  • 2\. acute suicidality (clinical assessment by study physician)
  • 3\. hypertension \> 180/100 mmHg (according to resting blood pressure, as assessed by study physician using blood pressure measurement)
  • 4\. hyperthyroidism that has not been sufficiently treated (clinical history by study physician and current thyroid parameters will have to be within the following ranges: TSH 0,34\-5,6 mU/l, fT3 3,2\-6,9 pmol/l, fT4 7,5\-21 pmol/l)
  • 5\. severe hepatic impairment (clinical history by study physician and current liver parameters will have to be within the following ranges: serum albumin \<2,8 g/dl serum bilirubin \> 3,0mg/dl, prothrombin time \< 40 % or INR \> 2,3\)
  • 6\. hypersensitivity to the active substance of esketamine or to any of the excipients listed in section 6\.1 of the SmPC (clinical history by study physician)
  • 7\. unstable angina or myocardial infarction in the last 6 months (clinical history by study physician)
  • 8\. Myocardial failure (clinical history and physical examination by study physician)
  • 9\. Glaucoma or perforating eye injuries (clinical history by study physician)
  • 10\. patients will be excluded if they have any drug or alcohol dependency/abuse within the previous three months or if they are under acute influence of alcohol (clinical assessment by study physician and alcohol breath test)

Investigators

Sponsor
Phillips Universität Marburg

Similar Trials

Active, not recruiting
Phase 1
The effects of esketamine and treatment expectation in acute major depressive disorderTo unravel the neural correlates of the interaction between positive expectation (high/low) and single dose antidepressant treatment (verum/placebo) with esketamine in patients with major depressive disorderMedDRA version: 20.0Level: SOCClassification code 10037175Term: Psychiatric disordersSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 21.1Level: LLTClassification code 10081270Term: Major depressive disorderSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 21.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2020-000784-23-DEPhilipps-Universität Marburg176
Recruiting
Phase 4
Positioning of Esketamine Treatment (PoET) in the real-world management of depressioMajor Depressive DisorderMental Health - Depression
ACTRN12623001068651orthern Sydney Local Health District162
Not yet recruiting
Phase 3
A randomised non-inferiority trial of esketamine versus electroconvulsive therapy in treatment-resistant depressiosadnessTreatment-resistant depression10027946
NL-OMON51415niversitair Medisch Centrum Groningen180
Completed
Not Applicable
Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve SurgeryDepression, AnxietyCardiac SurgeryS-ketamine
NCT06608030Chinese PLA General Hospital142
Completed
Not Applicable
The influence of esketamine analgesia on emotional distress of palliative inpatients. A retrospective analysis.Emotional distress caused by symptoms of depression and anxietyPain
DRKS00013208Interdisziplinäres Zentrum für Palliativmedizin der Universitätsklinik Düsseldorf16